HC Wainwright Boosts Insmed (NASDAQ:INSM) Price Target to $120.00

Insmed (NASDAQ:INSM - Get Free Report) had its price objective boosted by HC Wainwright from $90.00 to $120.00 in a report released on Wednesday,Benzinga reports. The firm presently has a "buy" rating on the biopharmaceutical company's stock. HC Wainwright's price objective indicates a potential upside of 21.54% from the company's previous close. HC Wainwright also issued estimates for Insmed's FY2025 earnings at ($5.05) EPS, FY2026 earnings at ($2.52) EPS, FY2027 earnings at $0.38 EPS, FY2028 earnings at $2.63 EPS and FY2029 earnings at $5.21 EPS.

INSM has been the subject of a number of other reports. Jefferies Financial Group reissued a "buy" rating on shares of Insmed in a research note on Tuesday. Guggenheim reaffirmed a "buy" rating and set a $101.00 target price on shares of Insmed in a research report on Tuesday, February 25th. Leerink Partners lifted their target price on Insmed from $100.00 to $115.00 and gave the company an "outperform" rating in a research report on Tuesday. UBS Group decreased their target price on Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Finally, Stifel Nicolaus decreased their target price on Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $104.81.

Insmed Trading Up 1.9%

Shares of NASDAQ:INSM traded up $1.85 during trading on Wednesday, hitting $98.73. The company had a trading volume of 5,318,455 shares, compared to its average volume of 2,164,284. The stock has a market cap of $17.98 billion, a price-to-earnings ratio of -17.66 and a beta of 0.80. Insmed has a one year low of $60.40 and a one year high of $100.00. The company has a fifty day simple moving average of $71.41 and a two-hundred day simple moving average of $73.61. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business had revenue of $92.82 million for the quarter, compared to the consensus estimate of $91.63 million. During the same period in the prior year, the business posted ($1.06) earnings per share. Insmed's revenue was up 22.9% on a year-over-year basis. As a group, equities analysts forecast that Insmed will post -4.56 earnings per share for the current year.

Insider Activity at Insmed

In related news, CEO William Lewis sold 18,750 shares of the company's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $77.03, for a total value of $1,444,312.50. Following the completion of the transaction, the chief executive officer now owns 334,186 shares of the company's stock, valued at approximately $25,742,347.58. This represents a 5.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Martina M.D. Flammer sold 9,925 shares of the company's stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $65.47, for a total value of $649,789.75. Following the completion of the transaction, the insider now directly owns 86,596 shares of the company's stock, valued at $5,669,440.12. The trade was a 10.28% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 319,932 shares of company stock valued at $25,733,693 in the last ninety days. Corporate insiders own 3.00% of the company's stock.

Hedge Funds Weigh In On Insmed

A number of hedge funds have recently made changes to their positions in the company. Cullen Frost Bankers Inc. boosted its position in shares of Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 221 shares during the period. Elequin Capital LP purchased a new position in shares of Insmed during the fourth quarter worth $28,000. Steward Partners Investment Advisory LLC boosted its holdings in Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 163 shares during the period. V Square Quantitative Management LLC boosted its holdings in Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 248 shares during the period. Finally, NBC Securities Inc. purchased a new position in Insmed in the first quarter valued at $49,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.